• 1
    1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41: 1-19.
  • 2
    Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008; 22: 489-496.
  • 3
    Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006; 20: 1645-1654.
  • 4
    Harvard Report on Cancer Prevention. Volume 1: Causes of human cancer. Cancer Causes Control 1996; 7( suppl 1): S3-S59.
  • 5
    Nutankalva L, Wutoh AK, McNeil J, et al. Malignancies in HIV: pre- and post-highly active antiretroviral therapy. J Natl Med Assoc. 2008; 100: 817-820.
  • 6
    Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007; 19: 446-451.
  • 7
    Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998; 351: 1833-1839.
  • 8
    Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008; 148: 728-736.
  • 9
    Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123: 187-194.
  • 10
    Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000; 92: 1500-1510.
  • 11
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 3030-3044.
  • 12
    Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol. 2002; 33: 392-404.
  • 13
    Ambinder RF. Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer. 2001; 37: 1209-1216.
  • 14
    Glaser SL, Lin RJ, Stewart SL, A et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997; 70: 375-382.
  • 15
    Spano JP, Atlan D, Breau JL, Farge D. AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Pt II: Cervical and anal squamous epithelial lesions, lung cancer, testicular germ cell cancers, and skin cancers. Eur J Intern Med. 2002; 13: 227-232.
  • 16
    MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol. 2008; 14: 1657-1663.
  • 17
    Newcomb-Fernandex J. Cancer in the HIV-infected population. Res Initiat Treat Action. 2003; 9: 5-13.
  • 18
    Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008; 22: 2143-2153.
  • 19
    Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003; 37: 292-298.
  • 20
    Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002; 63: 179-186.
  • 21
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370: 59-67.
  • 22
    Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003; 32: 527-533.
  • 23
    Vajdic CM, van Leeuwen MT. What types of cancers are associated with immune suppression in HIV? Lessons from solid organ transplant recipients. Curr Opin HIV AIDS. 2009; 4: 35-41.
  • 24
    Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362: 22-29.
  • 25
    Bouvard V, Baan R, Straif K, et al. A review of human carcinogens—pt B: biological agents. Lancet Oncol. 2009; 10: 321-322.
  • 26
    Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002; 16: 1155-1161.
  • 27
    Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001; 285: 1736-1745.
  • 28
    Clifford GM, Rickenbach M, Polesel J, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008; 22: 2135-2141.
  • 29
    Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008; 22: 841-848.
  • 30
    Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005; 104: 1505-1511.
  • 31
    Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003; 21: 3447-3453.
  • 32
    Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009; 23: 41-50.
  • 33
    Spano JP, Atlan D, Breau JL, Farge D. AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Pt I: Kaposi's sarcoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. Eur J Intern Med. 2002; 13: 170-179.
  • 34
    Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004; 164: 2349-2354.
  • 35
    Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; 24( suppl 3): S3/11-S3/25.
  • 36
    Adjei AA, Rajkumar SV, Tefferi A. Cancer symposium for the practitioner: introduction to solid tumors. Mayo Clin Proc. 2007; 82: 107-109.
  • 37
    Doll R. An epidemiological perspective of the biology of cancer. Cancer Res. 1978; 38: 3573-3583.
  • 38
    Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006; 108: 3786-3791.
  • 39
    Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009; 10: 1152-1159.
  • 40
    Flanders WD, Lally CA, Zhu BP, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res. 2003; 63: 6556-6562.
  • 41
    Biggar RJ, Melbye M. Marital status in relation to Kaposi's sarcoma, non-Hodgkin's lymphoma, and anal cancer in the pre-AIDS era. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 11: 178-182.
  • 42
    Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci. 2004; 328: 57-63.
  • 43
    Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008; 22: 1203-1211.
  • 44
    Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2009.
  • 45
    Cancer Statistics Registrations. MB1 No. 37, 1-86. London, UK: Office for National Statistics; 2006.
  • 46
    Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349: 1993-2003.
  • 47
    Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007; 21: 1957-1963.
  • 48
    START Protocol Synopsis. Available at: Accessed November 19, 2009.